Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd, together with its subsidiaries, researches and develops therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. Its lead candidate, Foralumab (TZLS-401), is a human anti-CD3 monoclonal antibody in Phase II clinical trials for non-active secondary progressive multiple sclerosis, Alzheimer's disease, multiple system atrophy, and amyotrophic lateral sclerosis. The company is also developing TZLS-501, a human anti-IL-6R monoclonal antibody, for autoimmune and inflammatory diseases. It is headquartered in London, the United Kingdom.